Acetylcysteine zinc

Identification

Name
Acetylcysteine zinc
Accession Number
DB14479
Description
Not Available
Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 389.75
Monoisotopic: 387.974121
Chemical Formula
C10H16N2O6S2Zn
Synonyms
  • N-acetyl-L-cysteine zinc salt
  • Zinc acetylcysteine

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
CarbamazepineAcetylcysteine zinc can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CeftibutenAcetylcysteine zinc can cause a decrease in the absorption of Ceftibuten resulting in a reduced serum concentration and potentially a decrease in efficacy.
CephalexinAcetylcysteine zinc can cause a decrease in the absorption of Cephalexin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CinoxacinAcetylcysteine zinc can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiprofloxacinAcetylcysteine zinc can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DeferasiroxAcetylcysteine zinc can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy.
DeferiproneAcetylcysteine zinc can cause a decrease in the absorption of Deferiprone resulting in a reduced serum concentration and potentially a decrease in efficacy.
DelafloxacinAcetylcysteine zinc can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DemeclocyclineAcetylcysteine zinc can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DolutegravirAcetylcysteine zinc can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Active Moieties
NameKindUNIICASInChI Key
Zinc cationionic13S1S8SF3723713-49-7PTFCDOFLOPIGGS-UHFFFAOYSA-N
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
DermaNICAcetylcysteine zinc (69.5 mg/1) + Chromium nicotinate (0.57 mg/1) + Ferrous cysteine glycinate (1.5 mg/1) + Folic acid (500 ug/1) + Hydroxocobalamin (15 ug/1) + Inositol nicotinate (328 mg/1) + Niacin (1.5 mg/1) + Nicotinamide (498 mg/1)TabletOralAllegis Pharmaceuticals, LLC2014-02-032016-12-01Us

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-acyl-l-alpha-amino acids. These are n-acylated alpha amino acids which have the L-configuration of the alpha-carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
N-acyl-L-alpha-amino acids
Alternative Parents
Cysteine and derivatives / Acetamides / Secondary carboxylic acid amides / Carboxylic acid salts / Organic transition metal salts / Monocarboxylic acids and derivatives / Carboxylic acids / Alkylthiols / Organonitrogen compounds / Organic zwitterions
show 3 more
Substituents
Acetamide / Aliphatic acyclic compound / Alkylthiol / Carbonyl group / Carboxamide group / Carboxylic acid / Carboxylic acid salt / Cysteine or derivatives / Hydrocarbon derivative / Monocarboxylic acid or derivatives
show 11 more
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
LP811J9FA1
CAS number
49793-39-7
InChI Key
KNVKDNCWDNRTOE-SCGRZTRASA-L
InChI
InChI=1S/2C5H9NO3S.Zn/c2*1-3(7)6-4(2-10)5(8)9;/h2*4,10H,2H2,1H3,(H,6,7)(H,8,9);/q;;+2/p-2/t2*4-;/m00./s1
IUPAC Name
zinc(2+) bis((2R)-2-acetamido-3-sulfanylpropanoate)
SMILES
[Zn++].CC(=O)N[[email protected]@H](CS)C([O-])=O.CC(=O)N[[email protected]@H](CS)C([O-])=O

References

General References
Not Available
ChemSpider
19055665

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.626 mg/mLALOGPS
logP1.33ALOGPS
logP-0.71ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)3.82ChemAxon
pKa (Strongest Basic)-2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area69.23 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity48.5 m3·mol-1ChemAxon
Polarizability15.05 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on July 06, 2018 15:32 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates